Barclays set a €72.00 ($83.72) price target on Merck KGaA (FRA:MRK) in a report published on Tuesday. The brokerage currently has a sell rating on the healthcare company’s stock.

MRK has been the subject of several other research reports. UBS Group set a €115.00 ($133.72) price target on shares of Merck KGaA and gave the company a buy rating in a research report on Tuesday, June 26th. Nord/LB set a €82.00 ($95.35) price target on shares of Merck KGaA and gave the company a neutral rating in a research report on Thursday, August 9th. Warburg Research set a €100.00 ($116.28) price target on shares of Merck KGaA and gave the company a neutral rating in a research report on Wednesday, September 12th. Goldman Sachs Group set a €92.00 ($106.98) price target on shares of Merck KGaA and gave the company a neutral rating in a research report on Wednesday, September 12th. Finally, Deutsche Bank set a €91.00 ($105.81) price target on shares of Merck KGaA and gave the company a neutral rating in a research report on Monday, July 30th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of €98.81 ($114.89).

Shares of MRK opened at €86.26 ($100.30) on Tuesday. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: Leveraged Buyout (LBO)

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.